top of page



The multidisciplinary research of our unit of excellence is reflected by collaborations between different groups belonging to the field of applied physics, applied mathematics, electronic engineering, bioinformatics, medical bioengineering, organic and pharmaceutical chemistry, pharmacology, biotechnology or experimental oncology among others. This multidisciplinarity has allowed an innovative research and the transference through the protection of knowledge in order to facilitate the use, application and exploitation outside the academic field, either with other R & D institutions, the productive sector or society in general. We have generated technological innovations, patents or utility models and even the creation of new

start-up and new Spinoffs.

Moreover, several members of the Unit are enrolled in the “Technology Promoters” pilot program of the TTO (Technology Transfer Office) of the University of Granada. At the moment, they have attending skill training activities and initiatives in innovation management, technology transfer, 

marketing and plan business that include topics about valorization and protection of research results, for instance, patents and utility models or the use of databases as sources of patent technology information.

We have a special interest in offering a necessary specialist training and invaluable expert mentoring for to develop and improve the valorization plan of the technology developed by the Unit. Also, we have as an objective for our PhD students and postdoctoral researcher to offer the possibility of establishing contact with businesses, entrepreneurs and investor that can give us the opportunity to elaborate an adequate commercialization/business plan that facilitates a possible spin-off /start-up creation. Definitely, we are convincing that our Mnat Unit must also require the transformation of scientific knowledge into a product that creates value in the society, increasing its success probabilities and facilitating access to markets for the benefit of the patients.

Cartilage 3D Scaffold.png
angel 5.png

Dual-guide RNA composition for executing a single-guide RNA CRISPR-Associated system

Number: EP23382131.3

Date: 2023


Hydrogel suitable to produce artificial tissues

Number: EP22382231.3

Date: 2022


CRISPNA for genome editing

Number: PCT/EP2021/087887

Date: 12/2021

Licensed by CRISPNABIO


Sonda oftalmológica de ondas de torsión

Number: P202130954, PCT/ES2022/070637, WO/2023/062260

Date: 11/10/2021


Dispositivo y método de cuantificación de elasticidad de la piel por ondas de torsión

Number: P202130760

Date: 04/08/2021


Braided fiber-reinforced composite post

Number: P202130436

Date: 11/05/2021


CRISPNA, a new tool for genome editing and diagnosis

Number: P202031322

Date: 30/12/2020


A medical device apparatus for the non-invasive transmission of focussed shear waves to impact cellular behaviour

Number: EP20382752.2, PCT/EP2021/072706, WO/2022/034237

Date: 14/08/2020


Transistor FET reconfigurable con dopado dual

Number: P202030318

Date: 20/04/2020


Polynucleotide for T cell specific transgen expression

Number: GENYO_19005

Date: 2020


Polinucleótido para expresión fisiológica en células T

Number: P202030955

Date: 2020


Composiciones para el tratamiento del cáncer, y específicamente de los sarcomas

Number: P202030148

Date: 2020


Método para predecir o pronosticar la respuesta al tratamiento del cáncer

Number: P202030147; WO2014122353

Date: 2020


Procedimiento de medida de grandes deformaciones de tracción de alta resolución

Number: P201930200, PCT/ES2020/070162

Date: 05/03/2019


Procedimiento de detección de radiación y partículas empleando un diodo semiconductor por modulación de bandas de energía

Number: P201831304

Date: 30/12/2018


Suspensiones Bimodales dentro del Límite Multidominio con Efecto Magneto-reológico Mejorado

Number: P201830726

Date: 18/07/2018


Polynucleotide for safer and more effective immunotherapies

Number: PCT/EP2019/081346; WO2020099572

Date: 2018

Licensed by LentiStem Biotech


Cancer treatment

Number: WO2017127892 A1; PCT/AU2017/050065

Date: 03/08/2017

Licensed by Propanc Biopharma, Inc


Ultrasonic low-frequency bioreactor as a selective therapy against cancer

Number: IPR-678

Date: 29/05/2017


Ultrasonic low frequency portable device for selective tumor therapy

Number: IPR-701

Date: 18/04/2017


Dispositivo transluminal y procedimiento para la caracterización mecánica de estructuras

Number: P201730415, PCT/ES2018/070243, WO/2018/172591, US17/602,400

Date: 24/03/2017


Phenol derivated to treat cancer

Number: WO16/174226A1; PCT/ES2016/059650

Date: 03/11/2016


Procedimiento de obtención de datos sobre la elasticidad de materiales empleando ondas de torsión

Number: P201630123, PCT/ES2017/070065, WO/2017/134327, US16/075,090

Date: 04/02/2016


[(Bencensulfonil)anilino]alquilos unidos a N-9 purinas substituidas a través de un enlace O, Nacetálico, que tienen como objetivo las células madre cancerosas para el tratamiento del cáncer

Number: P201630715

Date: 2016


Lent-On-Plus system for conditional expression in human Stem Cells

Number: P201631406;  WO2018083274

Date: 2016

Licensed by LentiStem Biotech


Use of Coenzyme Q biosenthetic proteins

Number: P201630630

Date: 2016


Research &
Development Contracts

Using Engineered DNA to Assess Spatial and Temporal Variation in eDNA
as a Measure of the Temporal and Spatial Variation of Biodiversity

through Cornell University USA
Reference: Contract OTRI (C4767-00)
PI: Francisco J. Rueda (UGR)
Funding: 83.660,00 $
Duration: 01/01/2021 - 19/09/2023


Bioimpresión 3D de cartílago y hueso con biotintas basadas en matriz
descelularizada (dECM) para la regeneración de lesiones osteocondrales

Source of funding: Fundación Mutua Madrileña
Reference: FMM-AP17196-2019
PI: Elena López Ruiz
Funding: 120.000,00 €
Duration: 01/10/2019 - 30/09/2022


Valorización de plataforma de inmunoterapia
Source of funding: Fundación para la Innovación y la Prospectiva en Salud en España
Reference: 3939-2
PI: Francisco Martín Molina
Funding: 29.000,00 €
Duration: 01/01/2021 - 31/12/2021


Development of biotinks and new marketable three-dimensional meshes for
3D bioprinting with application in regenerative medicine and cell therapy

Source of funding: Bioibérica (Barcelona)
PI: Juan Antonio Marchal
Funding: 81.200,00 €
Duration: 01/01/2012 - 31/12/2021


Detección RApida de INmunoglobulinas (IgA secretora, IgGs e IgMs)

parael diagnóstico precoz del SARS-COV-2 mediante un biosensor portátil

de grafeno
Source of funding: Fondo Supera COVID, CRUE-Banco Santander
Reference: DRAINCOV
PI: Francisco Gamiz
Funding: 110.000,00 €
Duration: 01/08/2020 - 31/10/2021


Identifying tissue and allele-specific vulnerabilities in oncogenic KRAS

Source of funding: Revolution Medicine Inc. (RevMED)

PI: Lukas E Dow
Funding: 765.435,00 $
Duration: 01/07/2020 - 01/07/2021


Toxina HokD como nueva herramienta terapéutica frente a células madre
cancerígenas derivadas de pacientes con cáncer de útero

Source of funding: Fundación Mutua Madrileña
Reference: FMM-AP16683-2017
PI: Houria Boulaiz Tassi
Funding: 121.690,00 €
Duration: 01/07/2017 - 30/06/2021


Tratamiento combinado con hiperoxia e inhibidores de PARP para
contrarrestar la progresión tumoral mediada por hipoxia

Source of funding: Fundación Domingo Martínez
PI: Javier Oliver Pozo
Funding: 100.000,00 €
Duration: 01/06/2019 - 31/05/2021


Dispositivo diagnostico 'Point of Care' para la deteccion RAPida de la

Source of funding: Fondo Supera COVID, CRUE-Banco Santander
Reference: RAPID-19
PI: Francisco Gamiz
Funding: 95.000,00 €
Duration: 15/06/2020 - 17/05/2021


Epi-transcriptomic small RNA modifications as predictive signatures for
therapy response in Diffuse Large B cell Lymphoma

Source of funding: KWF - Dutch Cancer Society
Reference: rc476
PI: Danijela Koppers-Lalic, Daphne de Jong, Michael Hackenberg
Funding: 547.890,00 €
Duration: 01/03/2017 - 28/02/2021


Metabolic and Immunological Vulnerabilities of Colorectal Cancer
Source of funding: Stand Up to Cancer Foundation (SUC2)/ American Association of
Cancer Research (AACR)
Reference: SU2C-AACR-DT22-17
PI: Lewis C Cantley (Weill Cornell Medicine)
Funding: 59.600,00 $ direct costs/year
Duration: 01/08/2019 - 31/07/2020


Desarrollo sintético de PRP y posterior validación del mismo
Source of funding: PROPANC BIOPHARMA (Australia)

PI: Macarena Perán Quesada
Funding: 91.754,00 €
Duration: 09/05/2018 - 09/05/2020


Extinciones Invisibles: Pérdida de diversidad en zonas áridas de la
Península Ibérica como consecuencia de la expansión de especies
vegetales asociadas al ser humano (ExIn)

Source of funding: Fundación BBVA
PI: José M. Gómez
Funding: 100.000,00 €
Duration: 01/01/2017 - 31/12/2019


Associated Start-ups 
& Spinoffs

Regemat 3D (

PKR-Exogenetics SL (16/12/2016 - 31/12/2021)

Oritia & Boreas Wind Engineering (

LentiStem Biotech (


Photo by J. M. Melchor

bottom of page